These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 14676228)

  • 1. Is impairment of ischaemic preconditioning by sulfonylurea drugs clinically important?
    Meier JJ; Gallwitz B; Schmidt WE; Mügge A; Nauck MA
    Heart; 2004 Jan; 90(1):9-12. PubMed ID: 14676228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest.
    Schwartz TB; Meinert CL
    Perspect Biol Med; 2004; 47(4):564-74. PubMed ID: 15467178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction.
    Garratt KN; Brady PA; Hassinger NL; Grill DE; Terzic A; Holmes DR
    J Am Coll Cardiol; 1999 Jan; 33(1):119-24. PubMed ID: 9935017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sulphonylurea treatment of NIDDM patients with cardiovascular disease: a mixed blessing?
    Leibowitz G; Cerasi E
    Diabetologia; 1996 May; 39(5):503-14. PubMed ID: 8739909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to letter by Wang et al.: Comparing cardioprotection by remote ischaemic preconditioning in patients with and without diabetics.
    Kottenberg E; Peters J
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):769. PubMed ID: 24850086
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparing cardioprotection by remote ischaemic pre-conditioning in patients with and without diabetes.
    Wang SY; Xue FS; Cui XL
    Acta Anaesthesiol Scand; 2014 Jul; 58(6):768. PubMed ID: 24773561
    [No Abstract]   [Full Text] [Related]  

  • 7. Variations in tissue selectivity amongst insulin secretagogues: a systematic review.
    Abdelmoneim AS; Hasenbank SE; Seubert JM; Brocks DR; Light PE; Simpson SH
    Diabetes Obes Metab; 2012 Feb; 14(2):130-8. PubMed ID: 21923736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impairment of myocardial protection in type 2 diabetic patients.
    Lee TM; Chou TF
    J Clin Endocrinol Metab; 2003 Feb; 88(2):531-7. PubMed ID: 12574175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.
    Cleveland JC; Meldrum DR; Cain BS; Banerjee A; Harken AH
    Circulation; 1997 Jul; 96(1):29-32. PubMed ID: 9236412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diabetes and coronary artery disease: time to stop taking the tablets.
    Edwards RJ; Rakhit RD; Marber MS
    Heart; 1999 Jun; 81(6):674. PubMed ID: 10979714
    [No Abstract]   [Full Text] [Related]  

  • 11. Exogenous calcium preconditions myocardium from patients taking oral sulfonylurea agents.
    Cain BS; Meldrum DR; Meng X; Pulido EJ; Shames BD; Selzman CH; Banerjee A; Harken AH
    J Surg Res; 1999 Oct; 86(2):171-6. PubMed ID: 10534420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myocardial protection by remote ischaemic pre-conditioning is abolished in sulphonylurea-treated diabetics undergoing coronary revascularisation.
    Kottenberg E; Thielmann M; Kleinbongard P; Frey UH; Heine T; Jakob H; Heusch G; Peters J
    Acta Anaesthesiol Scand; 2014 Apr; 58(4):453-62. PubMed ID: 24548338
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sulfonylureas and the risk of myocardial infarction.
    Thisted H; Johnsen SP; Rungby J
    Metabolism; 2006 May; 55(5 Suppl 1):S16-9. PubMed ID: 16631805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sulfonylurea derivatives in cardiovascular research and in cardiovascular patients.
    Schotborgh CE; Wilde AA
    Cardiovasc Res; 1997 Apr; 34(1):73-80. PubMed ID: 9217875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pro- and Antiarrhythmic Actions of Sulfonylureas: Mechanistic and Clinical Evidence.
    Leonard CE; Hennessy S; Han X; Siscovick DS; Flory JH; Deo R
    Trends Endocrinol Metab; 2017 Aug; 28(8):561-586. PubMed ID: 28545784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of sulfonylurea drugs is underappreciated.
    Lin WH; Wright JM
    J Am Coll Cardiol; 2000 Mar; 35(3):820-1. PubMed ID: 10716492
    [No Abstract]   [Full Text] [Related]  

  • 17. Protective ischaemia in patients: preconditioning and postconditioning.
    Granfeldt A; Lefer DJ; Vinten-Johansen J
    Cardiovasc Res; 2009 Jul; 83(2):234-46. PubMed ID: 19398470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulfonylureas as initial treatment for type 2 diabetes and the risk of adverse cardiovascular events: A population-based cohort study.
    Filion KB; Douros A; Azoulay L; Yin H; Yu OH; Suissa S
    Br J Clin Pharmacol; 2019 Oct; 85(10):2378-2389. PubMed ID: 31276600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Sulphonylurea derivatives and the cardiovascular system].
    Filipiak KJ
    Przegl Lek; 2000; 57 Suppl 4():19-22. PubMed ID: 11293225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applications.
    Riveline JP; Danchin N; Ledru F; Varroud-Vial M; Charpentier G
    Diabetes Metab; 2003 Jun; 29(3):207-22. PubMed ID: 12909809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.